Medicamen Biotech Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Medicamen Biotech Share Price

225.801.50 (0.67%)

Closed
As On: 18 Jun, 2026, 03:59 PM IST
As On: 18 Jun, 2026, 03:44 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	224.00
High	228.95
Low	220.00
Prev Close	224.30
Volume	23,143
VWAP(₹)	224.33

Key Metrics

PE Ratio(x)	28.19
EPS - TTM(₹)	8.01
MCap(₹ Cr.)	306.25
MCap Rank	101
PB Ratio(x)	1.10
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	447.65
52W Low(₹)	216.95
MCap/Sales	1.54
Beta(1 Month)	-
BV/Share(₹)	203.17

Medicamen Bio share price insights

Quarterly Topline Performance
Company witnessed QoQ revenue growth of 31.49%, which is highest in the last 3 years. (Source: Consolidated Financials)
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 19.01% outperformed its 3 year CAGR of 11.78%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 1.77% of its operating revenues towards interest expenses and 17.54% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Medicamen Bio Share Price Update
Medicamen Biotech Ltd. share price moved up by 0.67% from its previous close of Rs 224.30. Medicamen Biotech Ltd. stock last traded price is 225.80
Share Price Value
Today/Current/Last 225.80222.30
Previous Day 224.30224.45

Found Insights useful?

Medicamen Bio Share Price Returns

1 Day	0.67%
1 Month	-16.03%
3 Months	-16.85%
1 Year	-45.27%
3 Years	-67.4%
5 Years	N.A.

Medicamen Bio Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Medicamen Bio Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	62.38	47.44	47.54	43.52	34.84
Total Income Growth (%)	31.49	-0.21	9.26	24.90	-23.06
Total Expenses	56.94	44.36	43.87	40.23	31.70
Total Expenses Growth (%)	28.36	1.12	9.05	26.91	-22.01
EBIT	5.44	3.08	3.67	3.28	3.14
EBIT Growth (%)	76.55	-16.04	11.80	4.59	-32.27
Profit after Tax (PAT)	3.86	2.19	2.67	2.15	2.42
PAT Growth (%)	76.36	-17.99	23.86	-10.89	-17.31
EBIT Margin (%)	8.72	6.50	7.72	7.55	9.01
Net Profit Margin (%)	6.18	4.61	5.61	4.95	6.94
Basic EPS (₹)	3.28	1.21	1.56	1.18	1.47

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	56.41	44.03	42.60	38.92	31.22
Total Income Growth (%)	28.12	3.35	9.45	24.68	-24.39
Total Expenses	52.28	40.16	38.99	36.19	27.56
Total Expenses Growth (%)	30.17	3.01	7.74	31.32	-25.67
EBIT	4.13	3.86	3.61	2.73	3.66
EBIT Growth (%)	6.86	7.06	32.10	-25.34	-13.09
Profit after Tax (PAT)	2.97	2.59	2.21	1.64	2.41
PAT Growth (%)	14.56	17.63	34.76	-32.08	-4.48
EBIT Margin (%)	7.32	8.78	8.47	7.02	11.72
Net Profit Margin (%)	5.27	5.89	5.18	4.21	7.72
Basic EPS (₹)	2.19	1.91	1.63	1.21	1.90

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	200.88	168.79	181.63	143.33	117.17
Total Revenue Growth (%)	19.01	-7.07	26.72	22.33	3.26
Total Expenses	188.90	158.91	168.56	126.28	99.07
Total Expenses Growth (%)	18.87	-5.72	33.47	27.47	2.06
Profit after Tax (PAT)	9.64	7.11	10.93	14.84	14.90
PAT Growth (%)	35.64	-34.97	-26.36	-0.36	22.82
Operating Profit Margin (%)	7.82	8.01	9.74	14.17	16.88
Net Profit Margin (%)	4.87	4.37	6.09	10.53	12.90
Basic EPS (₹)	7.22	5.16	7.50	11.92	12.19

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	181.95	157.69	174.69	140.35	117.17
Total Revenue Growth (%)	15.39	-9.73	24.47	19.78	5.65
Total Expenses	170.40	144.91	157.80	123.01	99.06
Total Expenses Growth (%)	17.59	-8.17	28.28	24.18	5.22
Profit after Tax (PAT)	9.41	9.45	13.30	15.00	14.91
PAT Growth (%)	-0.41	-28.96	-11.36	0.64	19.38
Operating Profit Margin (%)	8.01	10.44	12.33	14.69	16.89
Net Profit Margin (%)	5.26	6.23	7.71	10.88	12.91
Basic EPS (₹)	6.94	7.43	10.50	12.04	12.20

All figures in Rs Cr, unless mentioned otherwise

Insights

Quarterly Topline Performance
Company witnessed QoQ revenue growth of 31.49%, which is highest in the last 3 years. (Source: Consolidated Financials)
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 19.01% outperformed its 3 year CAGR of 11.78%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	371.99	297.15	294.55	278.52	225.69
Total Assets Growth (%)	25.19	0.88	5.76	23.41	16.33
Total Liabilities	96.44	84.10	87.57	85.10	79.22
Total Liabilities Growth (%)	14.67	-3.96	2.89	7.42	29.63
Total Equity	275.55	213.05	206.98	193.41	146.47
Total Equity Growth (%)	29.33	2.93	7.02	32.05	10.22
Current Ratio (x)	2.54	2.11	1.89	1.98	1.69
Total Debt to Equity (x)	0.17	0.16	0.15	0.13	0.17
Contingent Liabilities	0.00	-	-	-	-

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	361.52	293.19	294.21	276.78	225.70
Total Assets Growth (%)	23.31	-0.35	6.30	22.63	17.27
Total Liabilities	81.79	75.55	85.01	82.99	77.66
Total Liabilities Growth (%)	8.26	-11.13	2.43	6.86	33.62
Total Equity	279.73	217.64	209.21	193.80	148.04
Total Equity Growth (%)	28.53	4.03	7.95	30.91	10.19
Current Ratio (x)	2.62	2.12	1.85	1.96	1.70
Total Debt to Equity (x)	0.13	0.13	0.14	0.13	0.16
Contingent Liabilities	0.00	1.89	8.94	8.56	5.85

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	-33.17	-8.16	-6.74	-6.29	4.11
Net Cash used in Investing Activities	-3.04	-1.40	-5.56	-5.88	-8.47
Net Cash flow from Financing Activities	63.72	-1.47	6.31	29.13	4.30
Net Cash Flow	27.50	-11.03	-5.99	16.95	-0.07
Closing Cash & Cash Equivalent	31.26	3.76	14.79	20.78	3.82
Closing Cash & Cash Equivalent Growth (%)	731.63	-74.57	-28.84	443.27	-1.69
Total Debt/ CFO (x)	-1.44	-4.08	-4.57	-3.84	5.93

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	-29.26	-2.63	-0.25	-3.50	4.81
Net Cash used in Investing Activities	-2.85	-1.72	-8.71	-7.54	-8.47
Net Cash flow from Financing Activities	59.61	-6.68	3.14	27.67	4.39
Net Cash Flow	27.50	-11.04	-5.82	16.63	0.73
Closing Cash & Cash Equivalent	31.08	3.58	14.62	20.44	3.81
Closing Cash & Cash Equivalent Growth (%)	768.19	-75.51	-28.48	435.87	23.68
Total Debt/ CFO (x)	-1.26	-10.33	-120.17	-6.91	5.06

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 3.04 cr for investing activities which is an YoY increase of 117.55%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	3.49	3.33	5.28	7.77	10.17
Return on Capital Employed (%)	5.45	5.95	8.32	10.19	12.74
Return on Assets (%)	2.59	2.39	3.71	5.32	6.60
Interest Coverage Ratio (x)	6.49	6.37	5.59	9.01	18.04
Asset Turnover Ratio (x)	0.59	0.55	0.63	0.56	0.55
Price to Earnings (x)	31.65	86.21	44.64	56.18	52.91
Price to Book (x)	1.11	2.87	2.35	4.35	5.37
EV/EBITDA (x)	14.03	31.93	20.48	31.62	31.94
EBITDA Margin (%)	11.47	12.36	13.70	18.69	21.88

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	3.36	4.34	6.35	7.78	10.06
Return on Capital Employed (%)	5.06	7.17	10.03	10.31	12.61
Return on Assets (%)	2.60	3.22	4.51	5.42	6.60
Interest Coverage Ratio (x)	7.68	7.48	6.46	9.10	18.05
Asset Turnover Ratio (x)	0.55	0.52	0.60	0.55	0.55
Price to Earnings (x)	32.47	64.94	36.76	55.56	52.91
Price to Book (x)	1.09	2.81	2.33	4.30	5.31
EV/EBITDA (x)	14.39	27.92	17.76	31.31	31.92
EBITDA Margin (%)	11.96	15.04	16.40	19.29	21.89

Found Financials useful?

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
No Data Available
Pivot Levels
R1 - Pivot
-
S1 -
R2 - S2 -
R3 - S3 -
Average True Range
5 Days 14 Days 28 Days
- - -

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Medicamen Bio	28.19	1.11	3.49	5.45	2.59	11.78	7.82	4.95	7.22	2.54	0.17	-1.44
SMS Lifesciences Ind	25.30	1.91	8.10	10.61	3.80	1.79	9.47	5.33	57.26	1.04	0.51	2.92
Albert David	-271.82	1.04	-0.38	0.78	-0.28	-1.49	0.94	-0.44	-2.62	3.24	0.07	-3.72
Bafna Pharma	32.90	7.13	0.00	-3.29	-34.67	9.31	-4.20	-57.54	-15.52	2.11	-0.71	-0.09
Medico Remedies	27.25	4.73	17.37	26.22	8.54	13.57	9.62	6.35	1.58	1.66	0.25	3.21
Add More

Annual Ratios (%)

Choose from Peers

Lyka Labs
Ambalal Sarabhai
Aarey Drugs
Nectar Lifesc
Brooks Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 54,87,095 40.46 % 0.00
Pledge 0 0.00 % 0.00
FII 13,281 0.10 % 0.08
DII 59,751 0.44 % -0.14
Others 80,02,688 59.44 % 0.35
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 40.46 40.46 40.46 40.46
Pledge 0.00 0.00 0.00 0.00
FII 0.10 0.02 0.05 0.00
DII 0.00 0.44 0.59 0.64
Mutual Funds 0.00 0.00 0.00 0.00
Others 59.44 59.08 58.90 58.90

Mutual Funds Ownership

No Data Available

Medicamen Bio Top Searches

Corporate Actions

Recent
Board Meeting
Final Dividend
May 20, 2026
Board Meeting
Quarterly Results
Feb 04, 2026
Board Meeting
Quarterly Results
Nov 06, 2025

Announced on	Meeting on
May 20, 2026	May 27, 2026
Final Dividend
Feb 04, 2026	Feb 13, 2026
Quarterly Results
Nov 06, 2025	Nov 14, 2025
Quarterly Results
Aug 07, 2025	Aug 12, 2025
Quarterly Results
May 22, 2025	May 30, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 30, 2025 Sep 19, 2025 10%
May 29, 2024 Sep 19, 2024 10%
Aug 11, 2023 Sep 20, 2023 10%
May 25, 2022 Sep 19, 2022 10%
Jun 28, 2021 Sep 16, 2021 10%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available

AGM/EGM Meetings

Announced on	Meeting on
Sep 11, 2025	Sep 26, 2025
-
Mar 03, 2025	Mar 26, 2025
-
Aug 16, 2024	Sep 25, 2024
Rs.1.0000 per share(10%)Final Dividend & A.G.M.
Aug 11, 2023	Sep 27, 2023
Rs.1.0000 per share(10%)Final Dividend & A.G.M.
Sep 11, 2020	Sep 25, 2020
Book closure from Sep 19, 2020 to Sep 25, 2020

About Medicamen Bio

Medicamen Biotech Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 306.25 Crore) operating in Pharmaceuticals sector.

Medicamen Biotech Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 62.38 Crore, up 31.49 % from last quarter Total Income of Rs 47.44 Crore and up 79.05 % from last year same quarter Total Income of Rs 34.84 Crore. Company has reported net profit after tax of Rs 4.45 Crore in latest quarter.

The company’s top management includes Mr.Rahul Bishnoi, Mr.Rajesh Madan, Mr.Ashwani Kumar Sharma, Mr.Sanjay Bansal, Mr.Suresh Kumar Singh, Dr.Vimal Kumar Shrawat, Mr.Arun Kumar, Mr.Harish Pande, Dr.Ravi Kumar Bansal, Ms.Sangeeta Bishnoi, Mrs.Sumita Dwivedi, Mr.Pratap Singh Rawat, Ms.Parul Choudhary. Company has Rai Qimat & Associates as its auditors. As on 31-03-2026, the company has a total of 1.36 Crore shares outstanding.

Medicamen Bio Share Price Today is Rs. 225.80. On previous day, the Medicamen Bio Share Price (NSE) closed at Rs. 227.8, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 40.46% of the stake in Medicamen Bio shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Medicamen Bio stocks was 0.1% as compared to 0.02% in Dec 2025 with increase of 0.08%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.44% as compared to 0.44% in Dec 2025 with decrease of 0.15%. Out of the total DII holdings in Medicamen Bio shares 0.0% was held by mutual funds. The rest including public held is 59.0%. Medicamen Bio stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Medicamen Bio Dividend: Ever since 1993, Medicamen Bio dividends has been paid out around 10 times. As on 18 Jun, 2026, 03:59 PM IST, The overall dividend yield for Medicamen Bio stands at 0.0%. The last dividend paid was on September 19, 2025 (Rs. 1.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 8.01.

Medicamen Bio Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 62.38 Cr. of sales and 31.49% of quarterly net profit, there have been multiple ups and downs in the Medicamen Bio stock prices in the past few weeks. For example, Medicamen Bio stock price on 10th of June 2026 was around Rs. 230.1. Medicamen Bio share price now stands at an average of Rs. 225.80. Judging by last week's performance, stock is in down trend.

Medicamen Bio has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Medicamen Bio share.

Historical Prices and Performance:
Medicamen Bio, incorporated in 1993 is a Small Cap company (with a market cap of Rs. 304.21) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Medicamen Bio stock was 3.49%, 3.33%, 5.28%, 7.77% and 10.17% respectively.
The Medicamen Bio share gave a 3 year return of -67.61% as compared to Nifty 50 which gave a return of 27.94%.
Medicamen Bio announced 10.0% final dividend on September 19, 2025.

Key Metrics:
PE Ratio of Medicamen Bio is 28.44
Prices/Sales Ratio of Medicamen Bio is 1.54
Price/Book Ratio of Medicamen Bio is 1.12

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Medicamen Bio, major competitors and peers include SMS Lifesciences Ind, Albert David, Bafna Pharma and Medico Remedies. As of Dec 2025, the dividend yield of Medicamen Bio stands at 0.0% while SMS Lifesciences Ind, Albert David, Bafna Pharma and Medico Remedies stand at 0.11%, 0.71%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 28.44 and 1.12 respectively.

Leadership of Medicamen Bio :
Parul Choudhary is Co. Secretary & Compl. Officer
Pratap Singh Rawat is Chief Financial Officer
Rajesh Madan is Chief Executive Officer
Rahul Bishnoi is Chairman
Ashwani Kumar Sharma is Non Executive Director
Vimal Kumar Shrawat is Non Executive Director
Sanjay Bansal is Non Executive Director
Suresh Kumar Singh is Non Executive Director
Arun Kumar is Independent Director
Harish Pande is Independent Director
Sangeeta Bishnoi is Independent Director
Ravi Kumar Bansal is Independent Director
Sumita Dwivedi is Independent Director
Parul Choudhary is Co. Secretary & Compl. Officer
Pratap Singh Rawat is Chief Financial Officer
Rajesh Madan is Chief Executive Officer
Rahul Bishnoi is Chairman
Ashwani Kumar Sharma is Non Executive Director
Vimal Kumar Shrawat is Non Executive Director
Sanjay Bansal is Non Executive Director
Suresh Kumar Singh is Non Executive Director
Arun Kumar is Independent Director
Harish Pande is Independent Director
Sangeeta Bishnoi is Independent Director
Ravi Kumar Bansal is Independent Director
Sumita Dwivedi is Independent Director
Parul Choudhary is Co. Secretary & Compl. Officer
Pratap Singh Rawat is Chief Financial Officer
Rajesh Madan is Chief Executive Officer
Rahul Bishnoi is Chairman
Ashwani Kumar Sharma is Non Executive Director
Vimal Kumar Shrawat is Non Executive Director
Sanjay Bansal is Non Executive Director
Suresh Kumar Singh is Non Executive Director
Arun Kumar is Independent Director
Harish Pande is Independent Director
Sangeeta Bishnoi is Independent Director
Ravi Kumar Bansal is Independent Director
Sumita Dwivedi is Independent Director
Parul Choudhary is Co. Secretary & Compl. Officer
Pratap Singh Rawat is Chief Financial Officer
Rajesh Madan is Chief Executive Officer
Rahul Bishnoi is Chairman
Ashwani Kumar Sharma is Non Executive Director
Vimal Kumar Shrawat is Non Executive Director
Sanjay Bansal is Non Executive Director
Suresh Kumar Singh is Non Executive Director
Arun Kumar is Independent Director
Harish Pande is Independent Director
Sangeeta Bishnoi is Independent Director
Ravi Kumar Bansal is Independent Director
Sumita Dwivedi is Independent Director
Parul Choudhary is Co. Secretary & Compl. Officer
Pratap Singh Rawat is Chief Financial Officer
Rajesh Madan is Chief Executive Officer
Rahul Bishnoi is Chairman
Ashwani Kumar Sharma is Non Executive Director
Vimal Kumar Shrawat is Non Executive Director
Sanjay Bansal is Non Executive Director
Suresh Kumar Singh is Non Executive Director
Arun Kumar is Independent Director
Harish Pande is Independent Director
Sangeeta Bishnoi is Independent Director
Ravi Kumar Bansal is Independent Director
Sumita Dwivedi is Independent Director
Parul Choudhary is Co. Secretary & Compl. Officer
Pratap Singh Rawat is Chief Financial Officer
Rajesh Madan is Chief Executive Officer
Rahul Bishnoi is Chairman
Ashwani Kumar Sharma is Non Executive Director
Vimal Kumar Shrawat is Non Executive Director
Sanjay Bansal is Non Executive Director
Suresh Kumar Singh is Non Executive Director
Arun Kumar is Independent Director
Harish Pande is Independent Director
Sangeeta Bishnoi is Independent Director
Ravi Kumar Bansal is Independent Director
Sumita Dwivedi is Independent Director
Parul Choudhary is Co. Secretary & Compl. Officer
Pratap Singh Rawat is Chief Financial Officer
Rajesh Madan is Chief Executive Officer
Rahul Bishnoi is Chairman
Ashwani Kumar Sharma is Non Executive Director
Vimal Kumar Shrawat is Non Executive Director
Sanjay Bansal is Non Executive Director
Suresh Kumar Singh is Non Executive Director
Arun Kumar is Independent Director
Harish Pande is Independent Director
Sangeeta Bishnoi is Independent Director
Ravi Kumar Bansal is Independent Director
Sumita Dwivedi is Independent Director
Parul Choudhary is Co. Secretary & Compl. Officer
Pratap Singh Rawat is Chief Financial Officer
Rajesh Madan is Chief Executive Officer
Rahul Bishnoi is Chairman
Ashwani Kumar Sharma is Non Executive Director
Vimal Kumar Shrawat is Non Executive Director
Sanjay Bansal is Non Executive Director
Suresh Kumar Singh is Non Executive Director
Arun Kumar is Independent Director
Harish Pande is Independent Director
Sangeeta Bishnoi is Independent Director
Ravi Kumar Bansal is Independent Director
Sumita Dwivedi is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

-

Address

1506, Chiranjiv Tower,43, Nehru Place,New Delhi, Delhi - 110019

Contact

cs@medicamen.com

http://www.medicamen.com

Executive Leadership

RB

Rahul Bishnoi

Chairman

RM

Rajesh Madan

Chief Executive Officer

AK

Ashwani Kumar Sharma

Non Executive Director

SB

Sanjay Bansal

Non Executive Director

Show More

Auditors

Rai Qimat & Associates

FAQs about Medicamen Bio share

1. What's the Medicamen Bio share price today?
As on 18 Jun, 2026, 03:59 PM IST Medicamen Bio share price is up by 0.67% basis the previous closing price of Rs 227.8. Medicamen Bio share price is Rs 225.80. Return Performance of Medicamen Bio Shares:
- 1 Week: Medicamen Bio share price moved up by 0.85%
2. What is the PE & PB ratio of Medicamen Bio?
The PE ratio of Medicamen Bio stands at 28.0, while the PB ratio is 1.1.
3. What are the returns for Medicamen Bio share?
Return Performance of Medicamen Bio Shares:
- 1 Week: Medicamen Bio share price moved up by 0.85%
4. What is the market cap of Medicamen Bio?
Medicamen Bio share has a market capitalization of Rs 306.25 Cr. Within Pharmaceuticals sector, it's market cap rank is 101.
5. What is 52 week high/low of Medicamen Bio share price?
Medicamen Bio share price saw a 52 week high of Rs 447.65 and 52 week low of Rs 216.95.

Top Gainers

As on 03:59 PM | 18 Jun 2026

789.90

111.40 (16.42%)

1,186.40

143.16 (13.73%)

163.00

16.35 (11.15%)

271.95

23.03 (9.26%)

New India Assurance

178.67

13.21 (7.99%)

Top Losers

As on 03:59 PM | 18 Jun 2026

82.31

-7.76 (-8.62%)

84.62

-5.74 (-6.36%)

1,812.40

-102.70 (-5.37%)

535.00

-23.65 (-4.24%)

1,119.40

-45.70 (-3.93%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.